What are the safe and effective treatment options for psoriasis in a patient with aplastic anemia, and which therapies should be avoided due to risk of further bone marrow suppression?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Psoriasis in Patients with Aplastic Anemia

For psoriasis in a patient with aplastic anemia, prioritize phototherapy (PUVA or narrowband UVB) as first-line systemic treatment, while strictly avoiding methotrexate, azathioprine, and hydroxyurea due to their bone marrow suppressive effects.

Critical Therapies to AVOID

The following agents are absolutely contraindicated in aplastic anemia due to bone marrow toxicity:

  • Methotrexate: Causes acute marrow suppression as a main side effect and is contraindicated in patients with pre-existing anaemia, leucopenia, or thrombocytopenia 1
  • Azathioprine: Main side effects include bone marrow toxicity and is contraindicated in severe anaemia 1
  • Hydroxyurea: Contraindicated in severe anaemia or leucopenia 1

These agents would further compromise an already failing bone marrow and risk life-threatening cytopenias.

Recommended Treatment Options

First-Line: Phototherapy

PUVA (psoralen plus ultraviolet A) is the preferred systemic approach as it is "probably the least toxic of all the systemic agents and is generally considered to be the systemic treatment of first choice" 1. PUVA:

  • Does not cause bone marrow suppression
  • Achieves clearance rates comparable to or better than biologics in short-term studies 2
  • Should be offered before oral systemic therapy 2

Narrowband UVB is an alternative that does not indicate increased risk of skin cancer in reviews 3 and avoids systemic exposure entirely.

Second-Line: Topical Therapies (Maximized)

Before considering any systemic agent, maximize topical approaches 4:

  • Calcipotriene plus betamethasone dipropionate: Combination therapy for up to 52 weeks is highly effective (69-74% achieving clear/almost clear status) 4
  • Vitamin D analogues alone: Safe for long-term use up to 52 weeks 4
  • Topical corticosteroids: No systemic bone marrow effects

Third-Line: Safer Systemic Options

If phototherapy and topical therapy fail:

Cyclosporin is the safest traditional systemic option:

  • No bone marrow toxicity listed as a primary concern 1
  • Main risks are renal dysfunction and hypertension (manageable with monitoring) 1
  • Effective in 60-80% of patients depending on dose 2
  • Requires monitoring of blood pressure and serum creatinine every 2 weeks initially, then monthly 1

Retinoids (acitretin, formerly etretinate):

  • No bone marrow suppression as a primary side effect 1
  • Particularly effective for pustular psoriasis 1
  • Main concerns are teratogenicity and lipid abnormalities, not hematologic 1

Biologic therapies (if available and affordable):

  • TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors 5, 6
  • Do not directly suppress bone marrow
  • Should be considered before conventional systemics per guidelines 2
  • Require screening for infections and malignancy risk assessment 3

Monitoring Considerations

For any systemic therapy chosen, weekly complete blood counts are mandatory given the underlying aplastic anemia. Any agent showing declining blood counts must be stopped immediately.

Important Caveats

  • Systemic corticosteroids should be avoided except for three specific emergencies: uncontrollable erythroderma with metabolic complications, von Zumbusch pustular psoriasis when other drugs contraindicated, or hyperacute psoriatic polyarthritis threatening irreversible joint damage 1

  • The combination of psoriasis and aplastic anemia is rare, but case reports show complete psoriasis remission following allogeneic bone marrow transplantation for aplastic anemia 7, 8, suggesting shared immune pathogenesis. If the patient is a transplant candidate for their aplastic anemia, this may resolve both conditions.

  • Drug interactions must be carefully reviewed—many medications can worsen bone marrow function or interact with treatments for aplastic anemia 9

References

Research

Treatments for psoriasis and the risk of malignancy.

Journal of the American Academy of Dermatology, 2009

Research

[Resolution of psoriasis vulgaris following allogeneic bone marrow transplantation for aplastic anemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 1996

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.